Granite Harbor Advisors’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$788K Buy
3,130
+119
+4% +$25.6K 0.31% 59
2026
Q1
$655K Buy
3,011
+216
+8% +$47.9K 0.29% 70
2025
Q4
$639K Sell
2,795
-38
-1% -$8.66K 0.27% 64
2025
Q3
$656K Buy
2,833
+282
+11% +$57.4K 0.28% 68
2025
Q2
$474K Buy
2,551
+396
+18% +$73.6K 0.22% 76
2025
Q1
$452K Buy
2,155
+326
+18% +$63.4K 0.24% 67
2024
Q4
$325K Buy
1,829
+29
+2% +$5.33K 0.18% 71
2024
Q3
$355K Buy
1,800
+423
+31% +$78.9K 0.21% 70
2024
Q2
$236K Buy
1,377
+10
+0.7% +$1.66K 0.15% 73
2024
Q1
$249K Buy
+1,367
New +$236K 0.17% 71

Other funds holding ABBV

Granite Harbor Advisors's ABBV Position: Q2 2026 in Review

Granite Harbor Advisors increased its AbbVie (ABBV) stake by 4% in Q2 2026, buying an estimated $25.6K and bringing the position to 3,130 shares worth $788K. The position accounts for 0.31% of the portfolio, ranked #59.

Granite Harbor Advisors first reported a position in ABBV in Q1 2024 and has held it in 10 quarters since. 4,195 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Granite Harbor Advisors held 3,130 shares of AbbVie worth $788K as of Q2 2026.
  • Granite Harbor Advisors bought 119 AbbVie shares in Q2 2026, an estimated $25.6K.
  • AbbVie made up 0.31% of Granite Harbor Advisors's portfolio in Q2 2026, its #59 holding.
  • Granite Harbor Advisors first reported a position in AbbVie in Q1 2024 and has held it in 10 quarters since.
  • 4,195 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Granite Harbor Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.